Items where authors include "Samson, A"

Article

Abraham, S and Samson, A orcid.org/0000-0002-3081-7850 (2023) Successful Rechallenge of Hepaftocellular Carcinoma with Atezolizumab and Bevacizumab Following Disease Progression. Annals of Clinical and Medical Case Reports, 10 (12). ISSN 2639-8109

Schuelke, MR, Gundelach, JH, Coffey, M et al. (7 more authors) (2022) Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances, 4 (1). pp. 1-10. ISSN 2632-2498

Samson, A orcid.org/0000-0002-3081-7850, West, EJ orcid.org/0000-0001-7449-120X, Carmichael, J et al. (27 more authors) (2022) Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 10 (6). pp. 745-756. ISSN 2326-6066

West, EJ, Scott, KJ, Tidswell, E et al. (11 more authors) (2022) Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. Cancers, 14 (9). 2181. ISSN 2072-6694

Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736

Liu, JKH, Irvine, AF, Jones, RL et al. (1 more author) (2022) Immunotherapies for hepatocellular carcinoma. Cancer Medicine, 11 (3). pp. 571-591. ISSN 2045-7634

Appleton, E, Hassan, J, Chan Wah Hak, C et al. (7 more authors) (2021) Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Frontiers in Immunology, 12. 754436. ISSN 1664-3224

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Kottke, T, Tonne, J, Evgin, L et al. (19 more authors) (2021) Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications, 12 (1). 1930. ISSN 2041-1723

Müller, LME, Migneco, G, Scott, GB et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426

Shaw, J, Gosein, R, Kalita, MM et al. (19 more authors) (2020) Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy. eLife, 9. e52555.

Driscoll, CB, Schuelke, MR, Kottke, T et al. (17 more authors) (2020) APOBEC3B-mediated Corruption of the Tumor Cell Immunopeptidome Induces Heteroclitic Neoepitopes for Cancer Immunotherapy. Nature Communications, 11. 790. ISSN 2041-1723

Müller, LME, Holmes, M, Michael, JL et al. (20 more authors) (2019) Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for ImmunoTherapy of Cancer, 7. 164. ISSN 2051-1426

Jennings, VA, Scott, GB orcid.org/0000-0003-0021-9400, Rose, AMS et al. (13 more authors) (2019) Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy, 27 (6). pp. 1139-1152. ISSN 1525-0016

Samson, A orcid.org/0000-0002-3081-7850, Bentham, MJ orcid.org/0000-0003-2439-3198, Scott, K orcid.org/0000-0002-5790-9579 et al. (15 more authors) (2018) Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, 67 (3). pp. 562-573. ISSN 0017-5749

Samson, A orcid.org/0000-0002-3081-7850, Scott, KJ orcid.org/0000-0002-5790-9579, Taggart, D et al. (36 more authors) (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 10 (422). eaam7577. ISSN 1946-6234

Conference or Workshop Item

Milhem, MM, Vanderwalde, AM, Bowles, TL et al. (16 more authors) (2022) Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Illinois.

Anthoney, A, Samson, A orcid.org/0000-0002-3081-7850, West, E et al. (14 more authors) (2018) Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, Il, USA.

Proceedings Paper

Harrington, K, Nenclares, P, Leslie, I et al. (21 more authors) (2022) 610 Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors. In: Journal for ImmunoTherapy of Cancer. SITC 37th Annual Meeting (SITC 2022), 08-12 Nov 2022, Boston, USA. BMJ , A642.

Milhem, M, VanderWalde, A, Bowles, T et al. (20 more authors) (2022) 611 Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial. In: Journal for ImmunoTherapy of Cancer. SITC 37th Annual Meeting (SITC 2022), 08-12 Nov 2022, Boston, USA. BMJ , A643-A643.

Samson, A orcid.org/0000-0002-3081-7850, West, E, Turnbull, S et al. (13 more authors) (2019) 1213P: Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. In: Abstract Book of the 44th ESMO Congress. European Society for Medical Oncology (ESMO) 2019 Congress, 27 Sep - 01 Oct 2019, Barcelona, Spain. Oxford University Press , v475-v532.

Douiyeb, S, Sigaloff, K, Samson, A et al. (8 more authors) (2019) Six versus four weeks of intravenous antibiotic treatment for staphylococcus aureus endocarditis: a pilot study. In: European Journal of Clinical Pharmacology. 14th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), 29 Jun - 02 Jul 2019, Stockholm, Sweden. Springer , S15.

Samson, A orcid.org/0000-0002-3081-7850, Scott, K orcid.org/0000-0002-5790-9579, Taggart, D et al. (7 more authors) (2017) Intravenous delivery of oncolytic reovirus to brain tumours in patients to immunologically prime for sequential checkpoint blockade. In: Neuro-Oncology. 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS), 04-07 May 2017, Zurich, Switzerland. Oxford University Press , iii53-iii53.